Russell Investments Group
AVTX icon

Russell Investments Group’s Avalo Therapeutics AVTX Stock Holding History

Russell Investments Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7K Buy
+3,341
New +$52.8K ﹤0.01% 3573
2018
Q2 		– Sell
-5
Closed -$61K – 2897
2018
Q1 		$61K Buy
+5
New +$56.3K ﹤0.01% 2807

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group's AVTX Position: Q2 2026 in Review

Russell Investments Group opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 3,341 shares worth $61.7K. The stake represents ﹤0.01% of the portfolio and ranks #3573 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in AVTX as recently as Q1 2018.

Russell Investments Group first reported a position in AVTX in Q1 2018 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Russell Investments Group held 3,341 shares of Avalo Therapeutics worth $61.7K as of Q2 2026.
  • Avalo Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3573 holding.
  • Russell Investments Group first reported a position in Avalo Therapeutics in Q1 2018 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.